ArticleGenes and immunity2005
The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status.
Article in Genes and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 205 citations in OpenAlex.
- PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis.The Journal of rheumatology · 2015Pooled it
- Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.Genes and immunity · 2012Pooled it
- Alleviation of experimental arthritis in SKG mice throughFrontiers in immunology · 2026Article
- Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development.Recent patents on nanotechnology · 2025Review
- Nod-like receptors in inflammatory arthritis.Biomedical journal · 2024Review
- Genetic Polymorphism ofMedicina (Kaunas, Lithuania) · 2022Review
- Rituximab used for simultaneous treatment of PR3-ANCA positive vasculitis associated with rheumatoid arthritis: A case report.Clinical case reports · 2020Article
- Osteoimmunology.Cold Spring Harbor perspectives in medicine · 2019Review
- Regulation of CD4Frontiers in immunology · 2019Review
- Immune-bone interplay in the structural damage in rheumatoid arthritis.Clinical and experimental immunology · 2018Review
- Regulation of autoimmune and anti-tumour T-cell responses by PTPN22.Immunology · 2018Review
- Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα.Science immunology · 2017Article
- Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.Iranian biomedical journal · 2017Article
- A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22.JCI insight · 2016Article
- Association of PTPN22 1858C→T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis.Rheumatology international · 2016Article
- The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.Cellular and molecular life sciences : CMLS · 2016Review
- The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA.Rheumatology (Oxford, England) · 2016Review
- Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome.SpringerPlus · 2015Article
- Protein tyrosine phosphatases as potential therapeutic targets.Acta pharmacologica Sinica · 2014Review
- PTPN22: the archetypal non-HLA autoimmunity gene.Nature reviews. Rheumatology · 2014Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
We have recently described the association between rheumatoid arthritis and a coding single-nucleotide polymorphism in the intracellular protein tyrosine phosphatase, PTPN22. The disease-associated polymorphism, 1858 C/T (rs2476601), encodes an amino-acid change (R620W) in one of four SH3 domain binding sites in the PTPN22 molecule. We have now extended our initial studies to address three questions: (1) Is the association with rheumatoid arthritis limited to rheumatoid factor (RF) positive disease? (2) Does homozygosity for PTPN22 R620W substantially increase disease susceptibility? (3) Is there an interaction between PTPN22 and the rheumatoid arthritis (RA)-associated HLA-DRB1 shared epitope alleles? A total of 1413 Caucasian rheumatoid arthritis patients and 1401 Caucasian controls were genotyped. The results support the view that PTPN22 was strongly and preferentially associated with RF positive disease (OR=1.75, 95% CI 1.46-2.10, P=1.3 x 10(-9)). The PTPN22 risk allele was not significantly associated with RF negative disease (OR=1.19, 95% CI 0.92-1.53, P=0.18), although a very weak association cannot be completely excluded. There was a strong dose effect on disease risk; two copies of the PTPN22 R620W allele more than doubles the risk for RF positive RA (OR=4.57, 95% CI 2.35-8.89). There was no evidence of a genetic association between PTPN22 and HLA susceptibility alleles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.